Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Höfler H, Kiechle M, Klijn JG, Schmitt M, Maier S, Foekens JA. Martens JW, et al. Among authors: portengen h. Cancer Res. 2005 May 15;65(10):4101-17. doi: 10.1158/0008-5472.CAN-05-0064. Cancer Res. 2005. PMID: 15899800
The prognostic value of BCAR1 in patients with primary breast cancer.
Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven SP, de Jong D, Peters HA, Portengen H, Meijer-van Gelder ME, Klijn JG, van Tienoven DT, Geurts-Moespot A, Span PN, Foekens JA, Sweep FC. Dorssers LC, et al. Among authors: portengen h. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6194-202. doi: 10.1158/1078-0432.CCR-04-0444. Clin Cancer Res. 2004. PMID: 15448007
How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.
Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA. Sieuwerts AM, et al. Among authors: portengen h. Clin Cancer Res. 2005 Oct 15;11(20):7311-21. doi: 10.1158/1078-0432.CCR-05-0560. Clin Cancer Res. 2005. PMID: 16243802
Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG, Foekens JA. Sieuwerts AM, et al. Among authors: portengen h. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3319-28. doi: 10.1158/1078-0432.CCR-06-0225. Clin Cancer Res. 2006. PMID: 16740753
CHEK2 1100delC and male breast cancer in the Netherlands.
Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M. Wasielewski M, et al. Among authors: portengen h. Breast Cancer Res Treat. 2009 Jul;116(2):397-400. doi: 10.1007/s10549-008-0162-7. Epub 2008 Aug 31. Breast Cancer Res Treat. 2009. PMID: 18759107
38 results